(2-methoxycarbonyl-4-nitrophenyl) β-D-galactopyranoside | 862125-41-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-methoxycarbonyl-4-nitrophenyl) β-D-galactopyranoside
• 英文别名: methyl 5-nitro-2-(β-D-galactopyranosyloxy) benzoate；methyl 5-nitro-2-(beta-D-galactopyranosyloxy)benzoate；methyl 5-nitro-2-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzoate
• CAS: 862125-41-5
• 化学式: C₁₄H₁₇NO₁₀
• 分子量: 359.29
• InChiKey: QHHAFRQRMQGAGQ-OIRVYTLQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  172
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (2-methoxycarbonyl-4-nitrophenyl) β-D-galactopyranoside 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 20.0h， 生成 methyl 5-amino-2-(β-D-galactopyranosyloxy) benzoate
  参考文献：
  名称：

  EP1712555

  摘要：

  公开号：
• 作为产物：
  描述：

  (2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl) 2-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)-5-nitrobenzoate 在 氨 作用下， 以 甲醇 为溶剂， 反应 28.0h， 以69%的产率得到(2-methoxycarbonyl-4-nitrophenyl) β-D-galactopyranoside
  参考文献：
  名称：

  Synthesis and evaluation of glycosyl donors with novel leaving groups for transglycosylations employing β-galactosidase from bovine testes

  摘要：

  Novel aryl beta-D-galactopyranosides were synthesized employing phase-transfer catalysis, and assayed as potential galactose donors in the presence of P-galactosidase from bovine testes using pNP-Gal as a reference. The aglycones were represented mainly by nitrophenols containing halogens, hydroxymethyl, aldehyde, carboxyl, ester or amino functions. An unusual intermolecular acetyl migration onto the benzylic alcohol group was observed during galactosylation of hydroxymethylnitrophenols. Pyridyl glycosides were obtained by reaction with the corresponding silver pyridinolates. Glycosides of halo-, hydroxymethyl- or methoxy-carbonyl-nitrophenols as leaving groups gave virtually the same yields of transglycosylation products. A minor increase was achieved with nitrosalicylaldehyde as leaving group, whereas carboxy or amino derivatives gave very low or no yield of the transglycosylation product. Commercially available donors such as resorufinyl and 4-methylumbelliferyl beta-D-galactopyranosides exhibited a lower transglycosylation potential than these novel pNP-Gal derivatives. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2006.10.014

文献信息

• Glycoside prodrug of 5- aminosalicylic acid
  申请人：Nakamura Akio

  公开号：US20070173461A1

  公开（公告）日：2007-07-26

  An object of the present invention is to provide a therapeutic agent for ulcerative colitis which allows 5-aminosalicylic acid (5-ASA) useful as a therapeutic agent for ulcerative colitis to be efficiently delivered to the large intestine of the affected site almost without being absorbed or metabolized in the stomach or the upper part of the small intestine and is safe and can be administered over a long term. The present invention relates to 5-ASA into which D-galactose represented by the following general formula [1] has been introduced. The compound of the present invention can be efficiently delivered to the large intestine of the site of action, and is degraded by the intestinal bacterial flora, whereby 5-ASA as the active ingredient can be produced in the large intestine.

  本发明的目的是提供一种治疗溃疡性结肠炎的治疗剂，该治疗剂允许将5-氨基水杨酸（5-ASA）作为治疗溃疡性结肠炎的有效药物，几乎不被胃或小肠上部吸收或代谢，并且是安全的，可以长期使用。本发明涉及将D-半乳糖引入以下通式[1]所表示的化合物中的5-ASA。本发明的化合物可以有效地输送到作用部位的大肠，并被肠道细菌群降解，从而在大肠中产生5-ASA作为活性成分。
• PRODRUG COMPRISING 5-AMINOSALICYLATE GLYCOSIDE
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1712555A1

  公开（公告）日：2006-10-18

  An object of the present invention is to provide a therapeutic agent for ulcerative colitis which allows 5-aminosalicylic acid (5-ASA) useful as a therapeutic agent for ulcerative colitis to be efficiently delivered to the large intestine of the affected site almost without being absorbed or metabolized in the stomach or the upper part of the small intestine and is safe and can be administered over a long term. The present invention relates to 5-ASA into which D-galactose represented by the following general formula [1] has been introduced. The compound of the present invention can be efficiently delivered to the large intestine of the site of action, and is degraded by the intestinal bacterial flora, whereby 5-ASA as the active ingredient can be produced in the large intestine.

  本发明的目的是提供一种治疗溃疡性结肠炎的药物，它能将作为溃疡性结肠炎治疗药物的5-氨基水杨酸（5-ASA）有效地输送到受影响部位的大肠，几乎不在胃或小肠上部被吸收或代谢，而且安全，可长期给药。本发明涉及 5-ASA，其中引入了由以下通式[1]表示的 D-半乳糖。 本发明的化合物可以有效地输送到作用部位的大肠，并被肠道细菌菌群降解，从而在大肠中产生作为活性成分的 5-ASA。